Header

Lung Cancer Clinical Trials

Category:Adult
Status:Active

Displaying Trial 1 - 30 of 75 in total

Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as etoposide, carboplatin and cisplatin, work in different ways to stop the growth of tumor cells, ei...

Diagnosis: Lung Cancer

Phase: 3

Protocol Number: 12-134

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

This randomized phase III trial studies proton chemoradiotherapy to see how well it works compared to photon chemoradiotherapy in treating patients with stage II-III non-small cell lung cancer that...

Diagnosis: Lung Cancer

Phase: 3

Protocol Number:

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and ...

Diagnosis: Lung Cancer

Phase: 3

Protocol Number: 15-702

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely remove...

Diagnosis: Lung Cancer

Phase: 3

Protocol Number: 15-701

Aspirin in Preventing Recurrence of Cancer in Patients With Node Positive Triple Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) breast cancer ...

Diagnosis: Lung Cancer, Breast: Early Stage Disease

Phase: 3

Protocol Number: 16-727

Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)

The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for...

Diagnosis: Lung Cancer

Phase: 3

Protocol Number: 16-459

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously ...

Diagnosis: Lung Cancer

Phase: 2 / 3

Protocol Number: 14-416

Afatinib With CT and RT for EGFR-Mutant NSCLC

This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Inv...

Diagnosis: Lung Cancer

Phase: 2

Protocol Number: 11-464

A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC

This research study is studying a type of radiation therapy called Stereotactic Body Radiation Therapy (SBRT) as a possible treatment for stage IV non-small cell lung cancer (NSCLC) that has a muta...

Diagnosis: Lung Cancer

Phase: 2

Protocol Number: 14-370

Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With Advanced Non-small Cell Lung Cancer Who Have Received One or Two Prior Lines of Therapy

A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) after one or two prior lines of syst...

Diagnosis: Lung Cancer

Phase: 2

Protocol Number: 15-387

A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor

This research study is studying capmatinib as a treatment for advanced non-small cell lung cancer with MET exon 14 skipping, where the participant has already received prior therapy with a MET inhi...

Diagnosis: Lung Cancer

Phase: 2

Protocol Number: 16-019

Merestinib In Non-Small Cell Lung Cancer And Solid Tumors

This research study is examining merestinib (a targeted therapy) as a possible treatment for non-small cell lung cancer (NSCLC) that was found to have a specific change in the MET gene (a MET exon ...

Diagnosis: Lung Cancer

Phase: 2

Protocol Number: 16-374

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone re...

Diagnosis: Lung Cancer, Breast: Metastatic

Phase: 2

Protocol Number: 16-216

Pleurectomy/Decortication Followed By Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma

For patients with this type of cancer, the standard of care is treatment with chemotherapy. Radiation therapy is typically not used. This is because radiation to the entire lining of the lung has m...

Diagnosis: Lung Cancer

Phase: 2

Protocol Number: 16-372

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

This randomized phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer. Drugs used in chemotherapy, such as car...

Diagnosis: Lung Cancer

Phase: 2

Protocol Number: 17-732

A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities

The purpose of this study is to determine the safety of TAS-120 and determine the most appropriate dose for the subsequent phase 2 safety and efficacy study in patients with advanced solid tumors a...

Diagnosis: Lung Cancer

Phase: 1 / 2

Protocol Number: 14-135

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

This research study is evaluating two drugs, alectinib and bevacizumab, as possible treatments for Advanced Non-Small Cell Lung Cancer (NSCLC).

Diagnosis: Lung Cancer

Phase: 1 / 2

Protocol Number: 15-055

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

This is the first human study to use X-396 (ensartinib), a drug being developed for treatment of advanced cancers. The initial purpose of the study is to determine the largest amount of X-396 that ...

Diagnosis: Lung Cancer

Phase: 1 / 2

Protocol Number: 15-461

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma

The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in patients with Non-small Cell Lung Cancer. Additionally the purpose of t...

Diagnosis: Lung Cancer

Phase: 1 / 2

Protocol Number: 15-322

Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

The purpose of this study is to evaluate the safety and efficacy of avelumab when combined with either crizotinib or PF-06463922.

Diagnosis: Lung Cancer

Phase: 1 / 2

Protocol Number: 15-479

A Trial of AP32788 in Non-Small Cell Lung Cancer

The purpose of this phase 1/2 study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of oral AP32788 in patients with non-small cell lung cancer (NSCLC). The trial will be condu...

Diagnosis: Lung Cancer

Phase: 1 / 2

Protocol Number: 16-143

MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

This first time in human study is intended for men and women at least 18 years of age who have advanced lung cancer which has grown or returned after being treated. In particular, it is a study for...

Diagnosis: Lung Cancer

Phase: 1 / 2

Protocol Number: 15-502

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ ad...

Diagnosis: Lung Cancer

Phase: 1

Protocol Number: 13-408

Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer

This research study is examining the benefit of a novel radiation planning approach on the likelihood of developing severe esophagitis (irritation and inflammation of the esophagus) during the cour...

Diagnosis: Lung Cancer

Phase: 1

Protocol Number: 15-023

Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer

Determine the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) of ACY 241 in combination with nivolumab.

Diagnosis: Lung Cancer

Phase: 1

Protocol Number: 16-156

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

This phase Ib trial studies the side effects and best dose of osimertinib and navitoclax when given together and to see how well they work in treating patients with previously treated epidermal gro...

Diagnosis: Lung Cancer

Phase: 1

Protocol Number: 16-714

A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

The purpose of this study is to evaluate f the treatment with NEO-PV-01 + adjuvant in combination with nivolumab is safe and useful for patients with certain types of cancer. The study also will in...

Diagnosis: Lung Cancer

Phase: 1

Protocol Number: 16-344

Phase 1, Dose Escalation Study of Pyrotinib in Patients Who Progressed on Prior HER2 Targeted Therapy

Part 1: to assess the safety and tolerability of pyrotinib and to define the maximum tolerated dose (MTD) of pyrotinib in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive adva...

Diagnosis: Lung Cancer

Phase: 1

Protocol Number: 16-265

Implementation of a System-level Tobacco Treatment Intervention

The proposed study plans to adapt and study the implementation and effectiveness of integrating Clinical and Community Effort Against Secondhand smoke Exposure (CEASE) into the thoracic oncology se...

Diagnosis: Lung Cancer

Phase: N/A

Protocol Number: 16-208

Pilot Study of a Pharmacy Intervention for Older Adults With Cancer

The purpose of this research study is to address the challenge of medication management for older patients undergoing treatment for cancer. The sponsor of this protocol is the Massachusetts General...

Diagnosis: Breast: Early Stage Disease, Lung Cancer, Gastrointestinal Malignancies

Phase: N/A

Protocol Number: 16-230

<< Previous 1 3
'